Horizon Therapeutics reports Q2 earnings miss; revises FY 2022 net sales and Adj.EBITDA guidance

Aug. 03, 2022 7:04 AM ETHorizon Therapeutics Public Limited Company (HZNP)By: Meghavi Singh, SA News Editor
  • Horizon Therapeutics press release (NASDAQ:HZNP): Q2 Non-GAAP EPS of $1.07 misses by $0.26.
  • Revenue of $876.4M (+5.3% Y/Y) misses by $62.42M.
  • Revises Full-Year 2022 Guidance: Full-Year 2022 Net Sales guidance of $3.53 Billion to $3.60 Billion vs. consensus of $3.96B, Full-Year 2022 Adjusted EBITDA guidance of $1.30 Billion to $1.35 Billion; Full-Year 2022 TEPEZZA Net Sales Percentage Growth in the High-Teens.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.